脊柱关节炎中白细胞介素-17和肿瘤坏死因子-α的免疫调节作用：聚焦于眼睛和中枢神经系统
Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.
作者信息
How Shing Koy Elsa, Labauge Pierre, Baillet Athan, Prati Clément, Marotte Hubert, Pers Yves-Marie
机构信息
Department of Rheumatology, Hôpital Nord, CHU Saint-Etienne, Saint-Etienne, France.
MS Unit, Department of Neurology, Montpellier University Hospital, Montpellier Cedex 5, France.
出版信息
Ther Adv Musculoskelet Dis. 2021 Jul 9;13:1759720X211025894. doi: 10.1177/1759720X211025894. eCollection 2021.
Abstract
Tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) are two pro-inflammatory cytokines involved in the pathophysiology of spondyloarthritis (SpA). Therapies targeting TNF-α or IL-17 are used as a second line among SpA patients failing non-steroidal anti-inflammatory drugs. The choice of such treatment has to take into account the patient's comorbidities. Neurologic diseases are common and their association with SpA deserves to be studied. Therefore, the role of TNF-α and IL-17 cytokines is worth investigating in these neuropsychiatric diseases. This review aimed to explore the role of TNF-α and IL-17 in the pathogenesis of uveitis, multiple sclerosis, neuromyelitis optica, Alzheimer's disease, Parkinson's disease and depression. This update is critical to guide the therapeutic management of these co-morbidities in SpA patients.
摘要
肿瘤坏死因子α（TNF-α）和白细胞介素-17（IL-17）是两种参与脊柱关节炎（SpA）病理生理过程的促炎细胞因子。对于非甾体抗炎药治疗失败的SpA患者，靶向TNF-α或IL-17的疗法被用作二线治疗。这种治疗的选择必须考虑患者的合并症。神经系统疾病很常见，它们与SpA的关联值得研究。因此，TNF-α和IL-17细胞因子在这些神经精神疾病中的作用值得探讨。本综述旨在探讨TNF-α和IL-17在葡萄膜炎、多发性硬化症、视神经脊髓炎、阿尔茨海默病、帕金森病和抑郁症发病机制中的作用。这一更新对于指导SpA患者这些合并症的治疗管理至关重要。
相似文献
1
Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system.脊柱关节炎中白细胞介素-17和肿瘤坏死因子-α的免疫调节作用：聚焦于眼睛和中枢神经系统
Ther Adv Musculoskelet Dis. 2021 Jul 9;13:1759720X211025894. doi: 10.1177/1759720X211025894. eCollection 2021.
2
Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.抗 TNF 治疗在脊柱关节炎及相关疾病中的应用，对免疫系统的影响及治疗反应预测。
Front Immunol. 2019 Mar 19;10:382. doi: 10.3389/fimmu.2019.00382. eCollection 2019.
3
Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?脊柱关节炎患者葡萄膜炎治疗的进展——是时候采用生物疗法了吗？
Rom J Ophthalmol. 2018 Apr-Jun;62(2):114-122.
4
Inflammatory pathways in spondyloarthritis.脊柱关节炎中的炎症通路。
Mol Immunol. 2014 Jan;57(1):28-37. doi: 10.1016/j.molimm.2013.07.016. Epub 2013 Aug 19.
5
Whodunit? The Contribution of Interleukin (IL)-17/IL-22-Producing γδ T Cells, αβ T Cells, and Innate Lymphoid Cells to the Pathogenesis of Spondyloarthritis.谁是罪魁祸首？白细胞介素（IL）-17/IL-22 产生的 γδ T 细胞、αβ T 细胞和固有淋巴细胞在脊柱关节炎发病机制中的贡献。
Front Immunol. 2018 Apr 25;9:885. doi: 10.3389/fimmu.2018.00885. eCollection 2018.
6
A referable clinical pattern of spondyloarthritis-associated uveitis.脊柱关节炎相关葡萄膜炎的可参考临床模式。
Rom J Ophthalmol. 2018 Apr-Jun;62(2):155-161.
7
Current Unmet Needs in Spondyloarthritis.当前脊柱关节炎的未满足需求。
Curr Rheumatol Rep. 2019 Jul 13;21(9):43. doi: 10.1007/s11926-019-0844-7.
8
Treatment of spondyloarthritis beyond TNF-alpha blockade.治疗肿瘤坏死因子-α阻断治疗之外的脊柱关节炎。
Best Pract Res Clin Rheumatol. 2014 Oct;28(5):819-27. doi: 10.1016/j.berh.2014.10.019. Epub 2014 Nov 18.
9
New immune cells in spondyloarthritis: Key players or innocent bystanders?脊柱关节炎中的新型免疫细胞：关键参与者还是无辜旁观者？
Best Pract Res Clin Rheumatol. 2015 Dec;29(6):706-14. doi: 10.1016/j.berh.2016.02.002. Epub 2016 Mar 12.
10
Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease.炎症性肠病相关性脊柱关节炎治疗管理的最新进展。
Clin Rheumatol. 2020 Dec;39(12):3543-3553. doi: 10.1007/s10067-020-05136-x. Epub 2020 May 18.
引用本文的文献
1
Exploring the causal relationships between spondyloarthritis/ankylosing spondylitis and intervertebral disc degeneration: a bidirectional Mendelian randomization study.探索脊柱关节炎/强直性脊柱炎与椎间盘退变之间的因果关系：一项双向孟德尔随机化研究。
J Orthop Surg Res. 2025 Aug 30;20(1):800. doi: 10.1186/s13018-025-06222-z.
2
CXCL10 Secreted by Pericytes Mediates TNFα-Induced Vascular Leakage in Tumors and Enhances Extravasation of Nanoparticle-Based Chemotherapeutics.周细胞分泌的CXCL10介导肿瘤中TNFα诱导的血管渗漏并增强基于纳米颗粒的化疗药物的外渗。
Cancer Res. 2025 May 2;85(9):1596-1610. doi: 10.1158/0008-5472.CAN-24-3833.
3
Distinct therapeutic effects of auraptene and umbelliprenin on TNF-α and IL-17 levels in a murine model of chronic inflammation.金松双黄酮和伞形花内酯对慢性炎症小鼠模型中肿瘤坏死因子-α和白细胞介素-17水平的不同治疗作用。
Heliyon. 2024 Nov 26;10(23):e40731. doi: 10.1016/j.heliyon.2024.e40731. eCollection 2024 Dec 15.
4
Bone metabolism and inflammatory biomarkers in radiographic and non-radiographic axial spondyloarthritis patients: a comprehensive evaluation.影像学和非影像学轴向脊柱关节炎患者的骨代谢和炎症生物标志物：综合评估。
Front Endocrinol (Lausanne). 2024 Feb 15;15:1227196. doi: 10.3389/fendo.2024.1227196. eCollection 2024.
5
The mosaic of autoimmunity - Finally discussing in person. The 13 international congress on autoimmunity 2022 (AUTO13) Athens.自身免疫性疾病的镶嵌现象 - 终于亲自讨论了。2022 年第 13 届自身免疫国际大会（AUTO13）在雅典举行。
Autoimmun Rev. 2022 Oct;21(10):103166. doi: 10.1016/j.autrev.2022.103166. Epub 2022 Aug 4.
6
Bioinformatics and Network Pharmacology Identify the Therapeutic Role and Potential Mechanism of Melatonin in AD and Rosacea.生物信息学和网络药理学鉴定褪黑素在 AD 和酒渣鼻中的治疗作用和潜在机制。
Front Immunol. 2021 Nov 23;12:756550. doi: 10.3389/fimmu.2021.756550. eCollection 2021.
本文引用的文献
1
Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.中轴型脊柱关节炎合并症的患病率和影响：系统评价和荟萃分析。
Rheumatology (Oxford). 2020 Oct 1;59(Suppl4):iv47-iv57. doi: 10.1093/rheumatology/keaa246.
2
Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects.多发性硬化症、视神经脊髓炎患者及健康受试者的血清白细胞介素-6和白细胞介素-17水平。
Int J Physiol Pathophysiol Pharmacol. 2019 Dec 15;11(6):267-273. eCollection 2019.
3
Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review.银屑病中的抑郁与自杀倾向以及布罗达单抗的临床研究：一项叙述性综述
Cutis. 2019 Dec;104(6):361-365.
4
PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.阿达木单抗治疗期间发生的进展型多发性硬化拓宽了抗TNF-α治疗相关脱髓鞘疾病的范围。
Ther Adv Neurol Disord. 2020 Jan 2;13:1756286419895155. doi: 10.1177/1756286419895155. eCollection 2020.
5
Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS).与中轴型脊柱关节炎患者生活质量较差相关的决定因素：英国风湿病学会生物制剂注册处（BSRBR-AS）的研究结果。
Ann Rheum Dis. 2020 Feb;79(2):202-208. doi: 10.1136/annrheumdis-2019-216143. Epub 2019 Oct 29.
6
Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease.两例优特克单抗成功治疗克罗恩病相关性非感染性葡萄膜炎的病例
J Crohns Colitis. 2020 May 21;14(4):571. doi: 10.1093/ecco-jcc/jjz167.
7
Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis.视神经脊髓炎谱系疾病患者中 Th17 细胞及其相关细胞因子的比例：一项荟萃分析。
Int Immunopharmacol. 2019 Oct;75:105793. doi: 10.1016/j.intimp.2019.105793. Epub 2019 Aug 8.
8
Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.司库奇尤单抗可能是合并中枢神经系统脱髓鞘疾病和强直性脊柱炎患者的有效治疗选择：两例临床病例报告。
Mult Scler Relat Disord. 2019 Oct;35:193-195. doi: 10.1016/j.msard.2019.08.006. Epub 2019 Aug 5.
9
Sleep and inflammation: partners in sickness and in health.睡眠与炎症：疾病与健康的伴侣。
Nat Rev Immunol. 2019 Nov;19(11):702-715. doi: 10.1038/s41577-019-0190-z.
10
Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis.司库奇尤单抗治疗一名强直性脊柱炎合并多发性硬化症患者的安全性和有效性。
Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1096. Epub 2019 Jun 28.
Zotero 插件